| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,071,108 ) |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI179616 | Modulation of chromatin dynamics to promote transplant survival | 000 | 2 | NIH | 11/5/2024 | $609,980 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R21AI182870 | Novel translational strategies to combat group B streptococcus infections | 000 | 1 | NIH | 11/12/2024 | $242,250 |
| | 2025 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | U54CA274375 | A single-cell spatial map characterizing the stromal TME in bladder and breast early-lesions | 000 | 3 | NIH | 10/11/2024 | $0 |
| | 2025 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | U54CA274375 | A single-cell spatial map characterizing the stromal TME in bladder and breast early-lesions | 001 | 3 | NIH | 10/18/2024 | $0 |
| | 2025 | 2023 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS115748 | Myelin Junction Therapy in Peripheral Neuropathies | 001 | 4 | NIH | 11/15/2024 | $231,174 |
| | 2025 | 2023 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS115002 | Genetic mechanism of conserved ancestral haplotype in SCA10 | 000 | 4 | NIH | 11/13/2024 | -$97 |
| | 2025 | 2023 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | K22CA248354 | The immunosuppressive function of secretory IgM in tumor-bearing mice | 000 | 3 | NIH | 10/11/2024 | -$3,107 |
| | 2025 | 2022 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA224304 | Self-assembled multifunctional aptamer-complex biomaterial for precision medicine | 000 | 5 | NIH | 11/5/2024 | -$9,093 |
| | 2025 | 2022 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AG057635 | Systematic Alzheimer's disease drug repositioning (SMART) based on bioinformatics-guided phenotype screening and image-omics | 000 | 5 | NIH | 10/11/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $56,535,988 ) (Continued on the next page) |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 000 | 1 | NIH | 2/2/2024 | $645,107 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 000 | 2 | NIH | 2/6/2024 | $442,928 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DE021863 | Outcome-Driven Approach to Minimize the Risks of Facial Distortion Following CMF Surgery | 000 | 9 | NIH | 7/24/2024 | $622,070 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R21CA280566 | Targeting metabolic stress response to improve CAR-T cell efficacy. | 000 | 1 | NIH | 6/14/2024 | $415,257 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 001 | 2 | NIH | 4/22/2024 | $24,608 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01EB035545 | Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety | 000 | 1 | NIH | 9/9/2024 | $391,588 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 001 | 3 | NIH | 9/12/2024 | $244,378 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI179616 | Modulation of chromatin dynamics to promote transplant survival | 001 | 1 | NIH | 9/5/2024 | $62,950 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI080779 | Modulation of innate immune cells to create transplant tolerance | 001 | 12 | NIH | 9/3/2024 | $48,448 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | T32NS126115 | T32 Administrative Supplement | 001 | 3 | NIH | 8/29/2024 | $29,710 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | T32NS126115 | T32 Administrative Supplement | 000 | 3 | NIH | 7/18/2024 | $204,214 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R37CA251318 | P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy | 000 | 6 | NIH | 6/12/2024 | $350,064 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R35GM137819 | Understanding the mechanisms that regulate cytoplasmic capping and defining its contributions to post-transcriptional gene regulation | 000 | 5 | NIH | 6/12/2024 | $403,750 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | K22NS112678 | Exploring functional complexes and disease networks within human RNA-binding protein interactomes | 000 | 4 | NIH | 6/12/2024 | $249,264 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI165372 | Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure | 001 | 3 | NIH | 6/27/2024 | $948,687 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01EY031588 | Cortical encoding of unconscious visual information and its impact on behavior | 002 | 6 | NIH | 7/11/2024 | $398,523 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 000 | 3 | NIH | 8/13/2024 | $336,483 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA284315 | Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC) | 000 | 2 | NIH | 7/19/2024 | $611,983 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA282099 | Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells | 000 | 2 | NIH | 7/19/2024 | $449,554 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI181635 | Natural Phenolic Compounds against Oral Candidiasis (OC) | 001 | 1 | NIH | 8/23/2024 | $0 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS129720 | “Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response” | 000 | 2 | NIH | 8/23/2024 | $511,747 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | K24AI121296 | POR and Training Program on Multidrug-Resistant Organisms | 000 | 9 | NIH | 6/14/2024 | $126,566 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI175699 | Deep Learning Based Pharmacokinetic Model for Vancomycin | 000 | 2 | NIH | 8/1/2024 | $470,454 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI181635 | Natural Phenolic Compounds against Oral Candidiasis (OC) | 000 | 1 | NIH | 8/9/2024 | $416,396 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01HL174587 | Advancing Endovascular PAD Treatment: Overcoming Critical Knowledge Gaps with MRI-histology | 000 | 1 | NIH | 6/15/2024 | $734,463 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA248111 | Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy | 000 | 5 | NIH | 7/31/2024 | $369,383 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS129788 | Relationship of the Human Astrocyte Matrisome with Synaptic Networks | 000 | 3 | NIH | 8/8/2024 | $426,548 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA244344 | Novel Targeted Therapeutics for Breast Cancer | 000 | 5 | NIH | 7/2/2024 | $351,075 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AA030965 | 4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | 001 | 2 | NIH | 7/26/2024 | $390,224 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DK137111 | Improving transplantation access, equity and outcomes through responsive risk communication and support for living donor candidates with obesity. | 001 | 2 | NIH | 7/2/2024 | $229,681 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R56AI132492 | Impact of Irreversible T Cell Dysfunction on Transplant Outcomes | 001 | 6 | NIH | 6/25/2024 | $32,300 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI080779 | Modulation of innate immune cells to create transplant tolerance | 000 | 12 | NIH | 6/21/2024 | $436,052 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DK137111 | Improving transplantation access, equity and outcomes through responsive risk communication and support for living donor candidates with obesity. | 002 | 2 | NIH | 8/20/2024 | $176,530 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01HL163535 | Human Atherogenesis with Underlying Dysfunctional HDL-Free Cholesterol | 001 | 2 | NIH | 6/21/2024 | $60,109 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DK134340 | A randomized, sham-controlled clinical trial evaluating individualized neuromodulation of cortical regions involved in neurogenic overactive bladder in Multiple Sclerosis | 001 | 2 | NIH | 5/24/2024 | $20,800 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS115748 | Myelin Junction Therapy in Peripheral Neuropathies | 001 | 5 | NIH | 5/3/2024 | $26,799 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS121405 | S100A4 mediated immune suppression in GBM | 001 | 4 | NIH | 5/3/2024 | $30,705 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA283580 | Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity | 000 | 1 | NIH | 5/22/2024 | $610,783 |
| | 2024 | 2024 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA175397 | Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches | 002 | 10 | NIH | 5/22/2024 | $363,685 |
|
| Loading… |
|
